Eagle Pharma (EGRX) Sell Off Overdone - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Eagle Pharma (EGRX) Sell Off Overdone - RBC
March 18, 2016 12:07 PM EDT
Piper Jaffray analyst David Amsellem lowered his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $98.00 (from $121.00) but maintained an Overweight rating after the company received a complete response letter (CRL) from the FDA related to its NDA for Kangio, its ready-to-use (RTU) form of bivalirudin. The... More
March 18, 2016 11:13 AM EDT
Mizuho Securities maintained a Buy rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $71.00 (from $81.00), on Kangio Delay. Eagle received a complete response letter (CRL) on Kangio, a reformulated version of MDCO's Angiomax. According to the letter, FDA wants further... More
March 18, 2016 6:52 AM EDT
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its KANGIO (bivalirudin injection), 505(b)(2) New Drug Application for a ready-to-use (RTU), stable liquid intravenous formulation of 5 mg/mL bivalirudin in a 50-mL vial... More
